Developing innovative laboratories via equipment funding

Industry: Life Sciences

Who are Curve Therapeutics?

Curve Therapeutics (‘Curve’) is a private biotechnology company located at the Southampton Science Park, on the south coast of England. Founded by Simon Kerry (PhD, MBA) and Professor Ali Tavassoli in 2019, and backed by blue chip investors, Curve pioneer a revolutionary intracellular screening platform that identifies therapies that positively impact the pathway of a disease. This innovative technology can facilitate the design and development of a pipeline of new small molecule drugs against cancers and other high priority disease targets, altering the disease process and improving patient outcomes.

The catalyst for change

In 2022, Curve signed an agreement with Merck Sharp and Dohme, one of the world’s largest pharmaceutical companies. Using their unique technology, Curve will use its technology to screen against five specific therapeutic targets. The research deal being worth up to US$1.7bn, should all five therapeutic programs succeed.

To conduct the required research, and to progress its in-house pipeline of innovative cancer drugs, Curve needed to increase the capacity and capability of their laboratories. By creating an environment with the latest cutting-edge scientific technology, they could also attract the brightest and highest calibre talent.

Accessing equipment finance

The life sciences industry is a well-connected and integrated ecosystem, with a culture of individuals and institutions working together. When procuring equipment, Curve was introduced to DLL by one of their laboratory equipment suppliers. By financing the equipment with DLL, Curve could access the latest scientific equipment, whilst preserving capital better used for expanding into their new research laboratory space.

"Our interactions with DLL have always been excellent and without your support we would not have been able to move into our new facilities and grow the team." says Simon Kerry.

On how DLL helped Curve, Karen Hill, DLL Sales Executive explains “The obvious benefit is that we are able to help organisations preserve their capital and keep budgeting simple and predictable. But what sets us apart is that through long standing relationships with many leading suppliers, DLL can combine the multiple needs of a customer into one simple finance solution.”

“DLL helps organisations get the mission critical equipment they need to advance their research and development objectives."

With the current ‘war for talent’, this can give the organisation a substantial competitive advantage, reducing an organisation’s go-to-market timeframe, getting them from concept to completion faster.”

Notes: Small molecule drug candidate: A chemical compound that may end up being developed into a drug, if it positively impacts the normal course of a diseased cell.

Explore more resources

BlogLife Sciences

Sharing in vibrant life science ecosystems

Sharing is at the heart of a vibrant life science ecosystem – sharing of knowledge, sharing of experience and, it would seem, sharing equipment that would otherwise be inaccessible. However, shared scientific equipment is only viable if three parts of the equation are balanced. First, you need to offer state-of the art equipment. Second, you need sufficient demand for the equipment, which means it only really works on larger campuses. Finally, the access, maintenance, and servicing require proactive monitoring and management on a day-to-day basis. Because of this, operating a shared scientific service has the potential to be expensive. However, there is new payment model that has the potential to reduce costs for the ecosystem operator – “Pay-per-use” (PPU).

BlogLife Sciences

How innovative financing equips state-of-the-art laboratories and attracts top talent

In the second of our regular series discussing challenges facing the UK life sciences industry, Dr Stephen Franklin reflects on his time as a PhD student, how he grappled with (and often lost against), obsolete and overworked equipment.

Customer StoriesLife Sciences

Supporting growth in life sciences. Laboratory equipment financing enables optimal use of resources

Nuclera, a UK-based biotechnology company, was founded in 2013 by three PhD students studying at the University of Cambridge. Whilst working on their dissertations, they found that the long lead time and high costs associated with protein prototyping created a significant barrier for scientists when it came to their research.

Advancing life sciences with financial solutions

DLL supports research, development and diagnosis with comprehensive finance offerings and industry expertise.